超声引导射频消融治疗腹壁子宫内膜异位症初步结果
本研究回顾性纳入19例腹壁子宫内膜异位症患者共29个病灶,采用超声引导下射频消融治疗,评估可行性、安全性及短期疗效。术后3个月病灶最大径、体积及VAS疼痛评分均较术前显著下降,仅观察到3例轻度不良事件。
要点
- 超声引导RFA术后3个月病灶最大径和VAS评分均较术前显著降低
- 29个病灶均采用局部麻醉联合静脉镇痛下移动式消融技术完成
- 仅观察到3例轻度不良事件,提示该技术短期安全性较好
核心结论
- 超声引导下射频消融是治疗腹壁子宫内膜异位症可行且安全的选择,可在短期内减轻疼痛程度并缩小病灶。
研究设计与样本
- AWE诊断依据临床症状及超声和磁共振影像表现,不典型病例行活检。
关键影像表现/征象
- 术前17例(89.5%)可触及肿块,2例(10.5%)有AWE手术史。
- 14例(73.7%)表现为周期性疼痛。
诊断标准与关键数值
- 术前平均VAS评分为7.37±1.42,术后3个月降至1.72±2.78(p<0.01)。
- 病灶平均最大径由术前25.1±17.47 mm降至术后3个月13.4±10.6 mm(p<0.01)。
- 病灶平均体积由术前5.65±7.41 mL降至术后3个月1.27±1.37 mL(p<0.01)。
- 并发症按SIR分级,共观察到3例轻度不良事件(15.8%)。
临床应用与阅片要点
- RFA采用18-gauge电极,在局部麻醉联合静脉镇痛下以移动式消融技术实施。
- 适用于有疼痛症状且超声或磁共振可见的腹壁子宫内膜异位症病灶。
局限性
- 回顾性单中心研究且样本量较小。
- 仅评估3个月短期疗效,长期复发与安全性尚待随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the feasibility, safety, and short-term outcomes of ultrasound-guided radiofrequency ablation (RFA) for abdominal wall endometriosis (AWE).
MATERIALS AND METHODS: This retrospective single-center study included 19 patients with AWE (mean age, 35.5 ± 5.0 years) with 29 lesions who underwent ultrasound-guided RFA between December 2023 and January 2026. AWE was diagnosed based on clinical symptoms and imaging findings on ultrasonography and magnetic resonance imaging; biopsy was performed in atypical cases. RFA was performed using an 18-gauge electrode with the moving-shot technique under local anesthesia combined with intravenous analgesia. Complications were classified according to the SIR classification. Short-term technical efficacy was assessed at 3 months based on clinical symptoms and changes in lesion size on imaging.
RESULTS: All patients presented with abdominal pain, including 14 patients (73.7%) with cyclic pain. The mean preprocedural VAS score was 7.37 ± 1.42. A palpable mass was present in 17 patients (89.5%), and two patients (10.5%) had a history of prior surgery for AWE. The mean maximum lesion diameter decreased from 25.1 ± 17.47 mm before treatment to 13.4 ± 10.6 mm at 3 months (p < 0.01). The mean lesion volume decreased from 5.65 ± 7.41 mL to 1.27 ± 1.37 mL (p < 0.01). The mean VAS score decreased to 1.72 ± 2.78 at 3 months (p < 0.01). Three mild adverse events (15.8%) were observed.
CONCLUSION: Ultrasound-guided RFA is a feasible and safe treatment option for AWE, providing short-term reductions in pain severity and lesion size.
引用
- Phan, Le, Nguyen, et al. Feasibility, safety, and short-term efficacy of ultrasound-guided radiofrequency ablation for abdominal wall endometriosis: preliminary results from a single center. Abdom Radiol (NY). 2026. PMID: 42667387. doi:10.1007/s00261-026-05766-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。